Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objectives of this study are to demonstrate that treatment with ABT-450/r/ABT-267 and ABT-333 administered with or without RBV has non-inferior efficacy (the percentage of subjects achieving SVR12, HCV RNA < LLOQ 12 weeks following treatment) compared to treatment with telaprevir and pegIFN/RBV and to compare the safety of the regimens in treatment-naive HCV genotype (GT) 1a- and 1b-infected adults without cirrhosis.
Critère d'inclusion
- Chronic Hepatitis C Infection